Skeletal muscle ageing throughout the life course (aged 18+ years) Musculoskeletal Diseases
Conditions
Interventions
Participants will undertake the intervention for up to 12 months. For single interventions (e.g. nitrate only, protein only, exercise only) participants will not be randomised. For comparisons with co
Sponsors
University of Bradford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers 2. Asymptomatic 3. 18+ years of age
Exclusion criteria
Exclusion criteria: 1. Previous history of muscle disorder 2. Cardiac issues 3. Medication which is known to affect muscles, including statins and steroids 4. Contraindications to exercise 5. Pregnant or breastfeeding 6. Known allergies 7. Volunteers on blood thinning medication 8. Known renal impairment 9. Adults lacking capacity (not compos mentis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical function measured using isokinetic dynamometer of knee extension and flexion at baseline and follow-up visits (baseline, 3, 6, 9, and 12 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Hand grip strength quantified using an isometric dynamometer at baseline, 3, 6, 9 and 12 months 2. Rate of force development, vertical peak force quantified by mid-thigh pulls using force plates, jump height, and concentric peak velocity quantified using a squat jump using force plates at baseline, 0, 3, 6, 9, and 12 months 3. Physical performance assessed using the short physical performance battery at baseline, 3, 6, 9 and 12 months 4. Physical performance assessed using the timed up-and-go test at baseline, 3, 6, 9 and 12 months 5. Body mass index (BMI) calculated by assessment of height and weight at baseline, 3, 6, 9 and 12 months 6. Weight, body mass index, fat mass, fat-free mass and muscle mass measured using bioelectrical impedance analysis (BIA) at baseline, 3, 6, 9 and 12 months 7. Blood and biopsy oxidative stress markers measured at baseline, 3, 6, 9 and 12 months: 7.1. DNA oxidation measured using a liquid chromatography–mass spectrometry (LC–MS) assay for 8-oxo-dG in white blood cells isolated from whole blood and muscle biopsies 7.2. Lipid peroxidation measured using the thiobarbituric acid reactive substance (TBARS) assay and ferrous oxidation xylenol orange (FOX) assay 7.3. Protein carbonyl levels measured using the dinitrophenylhydrazine assay 7.4. Bioavailability of the nitrate intervention measured using plasma nitrate and nitrite levels determined by high-performance liquid chromatography (HPLC)/LC-MS assay | — |
Countries
England, United Kingdom
Outcome results
None listed